Who are your closest competitors?
AI ranks the most relevant trials and assets by indication, mechanism, modality, phase, population, endpoints and study-design similarity.
Competitive intelligence for clinical development
Know which competitors could change your clinical programme.
TrialKey uses AI to identify the closest competitor trials, estimate when they may report, model their probability of success and assess the potential impact on your programme.
See the competitive landscape around your asset.
Bring an indication, mechanism, treatment or development plan.
570,000+ trials analysedAI-ranked competitor relevanceExpert-reviewed interpretation
Competitive intelligence command view
From competitor discovery to decision
Continuously structured evidence01
Who are your closest competitors?
AI ranks the most relevant trials and assets by indication, mechanism, modality, phase, population, endpoints and study-design similarity.
02
When are they likely to report?
Estimate readout windows from trial status, milestones, enrolment, duration and patterns from comparable clinical studies.
03
What is their probability of success?
Model competitor probability of success, uncertainty and the design factors most likely to influence the result.
04
What could the impact be?
Assess how success, failure or delay could change differentiation, evidence requirements, development timing and strategic value.
Prioritise the trials, readouts and evidence shifts that warrant action now.
The four answers
Competitive intelligence built around your programme.
A conventional pharmaceutical landscape produces a long competitor list. TrialKey ranks which programmes matter, when their evidence may arrive, how likely they are to succeed and what each result could mean for your clinical development strategy.
When are they likely to report?
Estimate readout windows from trial status, milestones, enrolment, duration and patterns from comparable clinical studies.
What is their probability of success?
Model competitor probability of success, uncertainty and the design factors most likely to influence the result.
What could the impact be?
Assess how success, failure or delay could change differentiation, evidence requirements, development timing and strategic value.
Competitive evidence views
See similarity, timing, probability and competitive impact together.
These anonymised examples show how TrialKey can turn a clinical trial landscape analysis into a decision system. The figures are illustrative; the structure reflects the outputs available for a programme-specific pharmaceutical competitive intelligence analysis.
Closest competitors, timing and likelihood
Similarity, reporting timeline and probability of success
Each bubble is an anonymised competitor trial. Position shows the observed or estimated reporting year and modelled probability of success; bubble size represents similarity to the selected programme.
Likely reporting timeline by similarity and PoS
ReportedUnreportedActiveExpected
20%30%40%50%Predicted success
Comparator median 31%
2024202520262027202820292030
Observed or estimated reporting year
Why similarity matters
The most strategically useful competitors are not always the largest programmes. TrialKey prioritises trials that resemble your indication, treatment approach, population and design.
Why timing matters
Upcoming and unreported trials can change the evidence standard, partnering narrative and differentiation required before your next decision gate.
Probability benchmark
Competitor probability of success
Modelled competitor trials are grouped into probability tiers so the selected programme can be interpreted against the relevant landscape rather than as a stand-alone score.
34
Lower
<25%
87
Mid
25–35%
46
High
35–45%
15
Leading
45%+
Mechanism landscape
Mechanism-of-action concentration
Comparator trials are grouped by inferred mechanism and technology class to reveal crowded development lanes, differentiated approaches and the depth of relevant precedent.
Neuroinflammation / immunomodulation40
Small-molecule neuroprotection26
Metabolic / mitochondrial22
Cell therapy / regenerative17
Genetic / antisense therapy13
Protein aggregation / proteostasis8
Illustrative comparator trial records
Technology benchmarking
Technology class vs probability
Predicted probability distributions are compared by mechanism and technology class. The diamond shows an illustrative observed success rate, making gaps between modelled design strength and historical outcomes visible.
Observed rateModelled distribution
Respiratory / supportive
Observed success 20%
Genetic / antisense
Observed success 15%
Oxidative stress
Observed success 8%
Cell therapy
Observed success 41%
Metabolic / mitochondrial
Observed success 27%
Neuroinflammation
Observed success 20%
0%20%40%60%
Predicted probability of success with observed outcome overlay
Technology positioning
Compare the range and median modelled outcomes across technology classes instead of relying on a single aggregate industry benchmark.
Interpret the gap
Differences between modelled and observed results can flag sparse precedent, heterogeneous trial designs, reporting bias or a class requiring deeper expert review.
Forward competitive monitoring
Competitive watchlist timeline
High-similarity unreported and active trials are prioritised by their expected readout timing, modelled probability of success and relevance to the selected programme.
Mechanism / programmeExpected readoutPoS · similarity
Programme A
Cell therapy
47% · 74% sim
Programme B
Neurotrophic support
42% · 69% sim
Programme C
Metabolic / mitochondrial
36% · 63% sim
Programme D
Hormonal modulation
31% · 62% sim
Programme E
Protein aggregation
34% · 81% sim
Programme F
Neuroinflammation
30% · 72% sim
Programme G
Small-molecule
38% · 64% sim
202520262027202820292030
Decision use: focus monitoring on the competitor readouts most likely to change your clinical evidence standard, programme positioning, protocol choices or financing narrative.
Identify the closest competitors
Rank relevance using indication, mechanism, modality, phase, population and trial-design similarity.
Estimate likelihood and impact
Model probability of success and assess what a positive, negative or delayed result could mean for your programme.
Maintain an active watchlist
Monitor the programmes and readouts most likely to change the competitive evidence landscape.
How the analysis works
From competitive search to an active clinical intelligence watchlist.
Machine-led discovery and comparison are combined with programme context and expert interpretation. The result is a competitive landscape that can be explained, monitored and used in real decisions.
Define the competitive question
Start with an indication, treatment, mechanism, asset or development decision. This keeps the analysis focused on the competitors capable of changing your programme.
Build the relevant trial landscape
Structure active, completed, unreported and planned studies across sponsors, mechanisms, modalities, populations, endpoints, geographies and development stages.
Rank, model and compare
Score similarity, model probability of success, estimate reporting windows and benchmark mechanism and technology classes against relevant evidence.
Translate signals into action
Create a competitive watchlist and assess implications for clinical trial design, evidence generation, positioning, investment and the next decision gate.
Decision-ready outputs
A competitive point of view, not a database export.
TrialKey connects competitor trial analysis with clinical development decisions. Outputs can support study design, portfolio strategy, business development, investment review, target product positioning and board-level discussion.
Traceable competitor and clinical-trial evidence
Comparable design and technology benchmarks
AI modelling with human expert interpretation
What the work can include
- AI-ranked competitor trials and pipeline assets
- Trial similarity and comparable-study analysis
- Competitor probability-of-success modelling
- Expected readout and reporting timeline
- Mechanism-of-action landscape and concentration
- Technology class vs probability benchmarking
- Competitive watchlist and catalyst monitoring
- Impact scenarios, strategic threats and opportunities
- Evidence gaps and expert-review questions
- Decision-ready report or working session
Where it fits
Use competitive intelligence before design—and keep it active afterwards.
The pharmaceutical competitive landscape informs development strategy, shapes trial design and feasibility, and creates a watchlist for the evidence events that may require a response.
Upstream
Clinical development strategy
Prioritise indications, evidence and development paths around the asset.
Landscape layer
Pharmaceutical competitive intelligence
Rank competitors, model likely outcomes and monitor readouts that could change the programme.
View this product in the solutions stackDesign response
Study design and feasibility
Respond through protocol design, evidence choices, countries, sites and execution planning.
Questions
Pharmaceutical competitive intelligence FAQs
What is pharmaceutical competitive intelligence?+
Pharmaceutical competitive intelligence is the structured analysis of competitor companies, pipeline assets, clinical trials, evidence, readouts and strategic activity. TrialKey focuses that landscape on a specific programme and the decisions its team needs to make.
How does TrialKey identify the closest competitor trials?+
TrialKey compares indication, treatment type, mechanism of action, modality, phase, population, endpoints, eligibility criteria, study design and available trial text. Similarity is used as a prioritisation signal and is reviewed alongside clinical context rather than treated as proof that two interventions are equivalent.
Can TrialKey estimate when competitor trials will report?+
Yes. Trial status, recruitment, enrolment, study duration, milestone dates and comparable-study patterns can be combined to estimate likely reporting windows. Timing remains an estimate, and uncertainty is kept visible in the competitive watchlist.
Can TrialKey predict a competitor trial's probability of success?+
Where the evidence supports it, TrialKey can model probability of success and compare the result with relevant trials, mechanisms and technology classes. Outputs are decision-support estimates, not guarantees, and are interpreted alongside data quality, uncertainty and expert clinical review.
What does the mechanism-of-action landscape show?+
The mechanism-of-action landscape groups relevant programmes into mechanistic and technology classes. It shows where activity is concentrated, where a programme may be differentiated and how much historical or active-trial precedent exists in each development lane.
What is included in a competitive watchlist?+
A competitive watchlist prioritises active and unreported programmes by relevance, expected readout timing, modelled probability of success and potential impact. It helps teams monitor the trials most likely to change the evidence standard or competitive narrative.
Map the competitive landscape
Know which competitor evidence deserves attention before your next decision.
Bring an indication, mechanism, treatment or development question. TrialKey can show the relevant competitor landscape, likely readouts, modelled success and strategic implications.